Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

Sasineprocel

Source date not recordedAnalyse record ↗

Personalized autologous dopaminergic-neuron precursor therapy in early clinical testing for Parkinson's disease.

Modality
autologous iPSC-derived dopaminergic neuronal precursor cell therapy
Availability (US)
Ongoing Phase 1/2a ASPIRO; cohorts 3 and 4 dosing complete as of June 30, 2026; investigational and not FDA-approved
Biomarkers
cell survival and engraftment imaging; dopamine-related function; motor and non-motor measures; safety and tolerability
Hallmark targeted
stem-cell exhaustion, loss of regenerative capacity, neurodegeneration
Kind
investigational cell therapy
Clinical trials
NCT06344026 — ASPIRO Phase 1/2a study in sporadic Parkinson's disease